Triple-negative breast cancer: understanding Wnt signaling in drug resistance

Triple-negative breast cancer (TNBC) is not as prevalent as hormone receptor or HER2-positive breast cancers and all receptor tests come back negative. More importantly, the heterogeneity and complexity of the TNBC on the molecular and clinical levels have limited the successful development of novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Merikhian, Parnaz, Eisavand, Mohammad Reza, Farahmand, Leila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353874/
https://www.ncbi.nlm.nih.gov/pubmed/34376211
http://dx.doi.org/10.1186/s12935-021-02107-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353874/
https://www.ncbi.nlm.nih.gov/pubmed/34376211
http://dx.doi.org/10.1186/s12935-021-02107-3

Ejemplares similares